Publications by authors named "Guelten Oskay-Ozcelik"
Article Synopsis
- The OTILIA study evaluated the safety and effectiveness of combining bevacizumab with standard chemotherapy in patients with advanced ovarian cancer, including a significant number of older patients (≥70 years).
- Results showed that while older patients experienced more severe adverse events, both age groups had similar progression-free survival rates (around 19.4 months).
- The study concluded that age should not be a limiting factor for using bevacizumab therapy, as effectiveness and tolerability were comparable between younger and older patients.
Epidemiological and cell culture studies indicate that ovarian carcinoma growth is dependent on estrogen stimulation. However, possibly due to the lack of a reliable biomarker that helps to select patients according to prognostically relevant estrogen receptor (ER) levels, clinical trials using anti-estrogenic therapeutics in ovarian carcinoma have had inconsistent results. Therefore, we tested if ER expression analysis by a quantitative method might be useful in this regard in formalin-fixed paraffin-embedded (FFPE) tissue.
View Article and Find Full Text PDFUnlabelled: The aim of this study was to investigate the influence of sex hormone levels on tumor biology and patients' outcome in ovarian cancer.
Patients And Methods: One hundred and six patients with ovarian cancer were enrolled into this prospective study. Serum and ascites samples were obtained intraoperatively.